NCT05383482View on ClinicalTrials.gov

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

June 25, 2024

Study Completion Date

December 31, 2025

Conditions
Solid TumorNSCLCCervical CancerEndometrial CancerEsophageal CancerGastric and Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Afuresertib

Afuresertib 125 mg PO on days 1-5, 8-12, 15-19 or Afuresertib 125 mg QD

DRUG

Nab paclitaxel

Nab-paclitaxel 80 mg/M2 IV D1,8, Q3W or 100 mg/M2 IV D1,8, Q3W

DRUG

Docetaxel

Docetaxel 50 mg/M2 IV D1 Q3W or Docetaxel 60 mg/M2 IV D1 Q3W

DRUG

Sintilimab

Sintilimab 200 mg Q3W

Trial Locations (5)

100142

Beijing Cancer Hospital, Beijing

Unknown

Chongqing Cancer Hospital, Chongqing

Jilin Cancer Hospital, Changchun

Zhongshan Hospital, Fudan University, Shanghai

West China Second University Hosital, Sichuan University, Chengdu

All Listed Sponsors
lead

Laekna Limited

INDUSTRY